Zur Kurzanzeige

2011-07-18Zeitschriftenartikel DOI: 10.1371/journal.pone.0019932
Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 - A Comparison of Two Methods; Germany, 2009/10.
dc.contributor.authorUphoff, Helmut
dc.contributor.authorHeiden, Matthias an der
dc.contributor.authorSchweiger, Brunhilde
dc.contributor.authorCampe, Hartmut
dc.contributor.authorBeier, Dietmar
dc.contributor.authorHelmeke, Carina
dc.contributor.authorLittmann, Martina
dc.contributor.authorHaas, Walter
dc.contributor.authorBuda, Silke
dc.contributor.authorFaensen, Daniel
dc.contributor.authorFeig, Marcel
dc.contributor.authorAltmann, Doris
dc.contributor.authorWichmann, Ole
dc.contributor.authorEckmanns, Tim
dc.contributor.authorBuchholz, Udo
dc.date.accessioned2018-05-07T14:42:23Z
dc.date.available2018-05-07T14:42:23Z
dc.date.created2011-08-09
dc.date.issued2011-07-18none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/rexSYzVnYrUOw/PDF/28K5hzF3i6Js.pdf
dc.identifier.urihttp://edoc.rki.de/176904/907
dc.description.abstractDuring the autumn wave of the pandemic influenza virus A/(H1N1) 2009 (pIV) the German population was offered an AS03- adjuvanted vaccine. The authors compared results of two methods calculating the effectiveness of the vaccine (VE). The test-negative case-control method used data from virologic surveillance including influenza-positive and negative patients. An innovative case-series methodology explored data from all nationally reported laboratory-confirmed influenza cases. The proportion of reported cases occurring in vaccinees during an assumed unprotected phase after vaccination was compared with that occurring in vaccinees during their assumed protected phase. The test-negative case-control method included 1,749 pIV cases and 2,087 influenza test-negative individuals of whom 6 (0.3%) and 36 (1.7%), respectively, were vaccinated. The case series method included data from 73,280 cases. VE in the two methods was 79% (95% confidence interval (CI) = 35–93%; P = 0.007) and 87% (95% CI = 78–92%; P,0.001) for individuals less than 14 years of age and 70% (95% CI =245%–94%, P = 0.13) and 74% (95% CI = 64–82%; P,0.001) for individuals above the age of 14. Both methods yielded similar VE in both age groups; and VE for the younger age group seemed to be higher.eng
dc.language.isoeng
dc.publisherRobert Koch-Institut, Infektionsepidemiologie
dc.subjectHumanseng
dc.subjectFemaleeng
dc.subjectGermany/epidemiologyeng
dc.subjectMaleeng
dc.subjectMiddle Agedeng
dc.subjectChildeng
dc.subjectAdolescenteng
dc.subjectAdulteng
dc.subjectCase-Control Studieseng
dc.subjectAgedeng
dc.subjectInfanteng
dc.subjectAge Distributioneng
dc.subjectLogistic Modelseng
dc.subjectMultivariate Analysiseng
dc.subjectVaccinationeng
dc.subjectTreatment Outcomeeng
dc.subjectYoung Adulteng
dc.subjectChild Preschooleng
dc.subjectAged 80 and overeng
dc.subjectInfant Newborneng
dc.subjectInfluenza Human/virologyeng
dc.subjectInfluenza Human/epidemiologyeng
dc.subjectInfluenza A Virus H1N1 Subtype/immunologyeng
dc.subjectInfluenza Human/immunologyeng
dc.subjectInfluenza Human/drug therapyeng
dc.subjectAdjuvants Immunologic/therapeutic use*eng
dc.subjectInfluenza Vaccines/immunologyeng
dc.subjectInfluenza Vaccines/therapeutic useeng
dc.subjectPandemics/prevention & controleng
dc.subject.ddc610 Medizin
dc.titleEffectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 - A Comparison of Two Methods; Germany, 2009/10.
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-10014858
dc.identifier.doi10.1371/journal.pone.0019932
dc.identifier.doihttp://dx.doi.org/10.25646/832
local.edoc.container-titlePLoS ONE
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttp://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0019932
local.edoc.container-publisher-namePublic Library of Science
local.edoc.container-volume6
local.edoc.container-issue7
local.edoc.container-year2011

Zur Kurzanzeige